Application prospects of human-originated hepatocellular carcinoma antibodies / 中国药理学通报
Chinese Pharmacological Bulletin
; (12)1986.
Article
en Zh
| WPRIM
| ID: wpr-555025
Biblioteca responsable:
WPRO
ABSTRACT
Non-surgical therapy is important to liver cancer treatment. Actinotheraphy and chemotherapy, because of their less specific for cancer tissue and serious side effect, badly affect the patients' life qualities, sometimes even endanger the patients lives. Hepatocellular carcinoma specific antibodies have been the focus of liver cancer biotherapy. After 20 years of study since 1975, it has been demonstrated that antibodies derived from mouse could not efficiently stimulate the functions of human reactor, but could induce human anti-mouse antibody responses which could bring about serious side effects. The application of DNA recombination technique provides a good method for resolving the immune selection problem. The techniques of humanoriginated antibodies and phage displaying will lead to development of innovative strategies to manage liver cancer. In our country, the antibody products aimed at cancer all originated from mouse while the study of human antibodies is still at its primary stage. Non-human antibodies has been forbidden in clinical trails by FDA in America since 2001. It can be speculated that human antibody products will domminate the future market rapidly.
Texto completo:
1
Base de datos:
WPRIM
Idioma:
Zh
Revista:
Chinese Pharmacological Bulletin
Año:
1986
Tipo del documento:
Article